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Abstract 
The formation of β-amyloid deposits is considered a histopathological feature of 
Alzheimer´s disease (AD). In vivo molecular imaging by means of amyloid-avid 
radiotracers will allow for an early and conclusive diagnostic of AD. Herein, we 
describe the radiosynthesis of the radiofluorinated styryl benzoxazole derivative [18F]-
[2-[N-methyl-N-(2`-fluoroethyl)-4`-aminostyryl]benzoxazole] ([18F]-1) and its pre-
clinical evaluation, including metabolic and biodistribution studies in male Wistar rat. 
The in vivo biological evaluation of [18F]-1 showed that this new radiotracer has a 
moderate brain uptake with a slow brain washout and a poor in vivo stability 
 
Highlights 
• Design of a fluorinated styryl benzoxazole derivative for detection of β-amyloid 
plaques. 
• Nucleophilic radiofluorination with readily available [18F]KF. 
• Metabolism and biodistribution studies of the radiofluorinated styryl 
benzoxazole derivative. 
 
1. Introduction 
Progressive neurodegenerative disorders such as Alzheimer´s (AD) or Parkinson´s 
(PD) disease affect millions of persons worldwide and pose a significant impact in 
public health, especially as more people approach old age. These diseases, known as 
“protein misfolding diseases” are characterized by the accumulation of insoluble protein 
deposits like β-amyloid (Aβ), neurofibrillar tangles in AD, and alpha-synuclein (αSyn) 
in PD. The molecular processes underlying these diseases are still not completely 
understood, but the deposition of the amyloid deposits is considered an early and 
specific event in their pathogenesis (Bacskai, Hickey et al. 2003; Irvine, El-Agnaf et al. 
2008). 
Being available suitable probes for in vivo targeting of Aβ deposits, the use of 
molecular imaging modalities is expected to demonstrate the locations and densities of 
such deposits in the AD brain allowing an early and assertive diagnosis of AD and/or 
the monitoring of anti-amyloidogenic therapies. Among the available molecular 
imaging modalities, positron emission tomography (PET) is the best suited to achieve 
such goal, particularly based on amyloid-avid molecules radiolabelled with the 
cyclotron produced radionuclides carbon-11 (11C) and fluorine-18 (18F) (Kung 2012; 
Lee, Choe et al. 2012; Ribeiro Morais, Paulo et al. 2012). 
A good performing PET radiotracer for in vivo imaging of amyloid deposits must 
show a high binding affinity to Aβ and a good permeability through the blood brain 
barrier (BBB), with minimal non-specific retention in the brain. Taking these requisites 
into consideration, a plethora of small-sized, planar and non-ionic 11C- and 18F-labelled 
molecules have been synthesized and evaluated as radiotracers for in vivo detection of 
Aβ deposits in AD-affected brain. From these studies, the Pittsburgh compound B 
([11C]PIB) (Fig 1) emerged as the gold standard PET radiotracer for in vivo β-amyloid 
imaging (Klunk, Engler et al. 2004). However, the short-life of 11C (t1/2 = 20.4 min) 
limits its use to centers with an on-site cyclotron. Hence, an intense research effort has 
been done to obtain alternative 18F-based radioprobes, as the longer half-life (t1/2 = 110 
min) of 18F allows for multistep radiosynthesis, longer in vivo investigation, and 
commercial distribution to other clinical PET centers. In recent years, encouraging 
results have been reported for a few 18F-labeled compounds (Fig. 1) (Liu, Kepe et al. 
2007; Choi, Golding et al. 2009; Jureus, Swahn et al. 2010; Vandenberghe, Van Laere 
et al. 2010; Barthel, Gertz et al. 2011; Clark, Schneider et al. 2011) that underwent 
clinical evaluation in humans as Aβ imaging agents. One of these agents, 18F-
Florbetapir (Amyvid) has been recently approved by the FDA for clinical use, giving in 
vivo PET images of amyloid deposits in close correlation with results from postmortem 
histopathological analysis (Clark, Schneider et al. 2011). 
Despite this success, there is still room to investigate alternative PET radioprobes 
for in vivo detection of amyloid aggregates, aiming at the finding of best performing 
compounds with augmented initial brain uptake and with reduced non-specific retention 
in the brain. For this purpose, we have designed a novel family of fluorinated styryl 
benzazole derivatives that interact in vitro with amyloid species in the same way as does 
Thioflavin T, which is a dye used to stain Aβ deposits in post-mortem histopathological 
studies. In this paper, we report on the radiosynthesis of one of these compounds, [18F]-
[2-[N-methyl-N-(2`-fluoroethyl)-4`-aminostyryl]benzoxazole] ([18F]-1), as well as on its 
in vivo evaluation that comprised biodistribution and metabolism studies in rat. 
Figure 1. 
2. Experimental Section 
2.1 Chemistry 
The tosylated precursor 2-[N-methyl-N-(2`-tosyloxyethyl)-4`-aminostyryl]benzoxazole 
(3) and the cold surrogate 2-[N-methyl-N-(2`-fluoroethyl)-4`-aminostyryl]benzoxazole 
(1) were synthesized according to previously reported (Ribeiro Morais, Miranda et al. 
2011). Briefly, 2-benzoxazolylmethyltriphenylphosphonium chloride (2.0 g, 4.6 mmol) 
in benzene (25 mL) was reacted with KtBuO (525 mg, 4.7 mmol) at rt. After 3 h, the 
reaction mixture was diluted with EtOAc (100 mL) and was extracted with water (100 
mL). The organic phase was dried over MgSO4, filtered and the filtrate was dried under 
vacuum. Then, the resulting phosphorane was refluxed overnight with N-methyl-N-(2-
tosyloxyethyl)-4 aminobenzaldehyde (590 mg, 1.8 mmol) in anhydrous THF (25 mL). 
Thereafter, the solvent was concentrated and the reaction crude was re-dissolved in 
CH2Cl2 (100 mL). The organic phase was extracted with sat. sol. of NaHCO3 (100 mL). 
The organic extract was dried over MgSO4, filtered and the filtrate was concentrated. 
Compound 3 (550 mg, 65 %) was purified by column column chromatography on silica 
gel (n-hexane/EtOAc/CHCl3 3:1:1). To a solution of 3 (250 mg, 0.55 mmol) in 
anhydrous THF (23 mL) was added anhydrous TBAF (1.8 mL, 1.8 mmol, 1.0 M in 
THF). The reaction mixture was refluxed for 30 minutes. Thereafter the solvent was 
concentrated; chloroform (50 mL) was added to the residue and was extracted with sat 
sol NaHCO3 (50 mL). The organic phase was dried over MgSO4, filtered and the filtrate 
was concentrated. Column chromatographic on silica gel (n-hexane/EtOAc 4:1) gave 
the mixture of 1-Z and 1-E (124 mg, 76%).  
 
2.2 Radiochemistry 
No-carrier-added aqueous [18F]fluoride was produced in a CYCLONE 18/9 cyclotron 
(IBA) by irradiation of [18O]H2O via the 18O(p,n)18F nuclear reaction. Resolubilization 
of the aqueous [18F]fluoride (0.8–1.0 GBq) was accomplished as described by Coenen 
et al (Coenen, Klatte et al. 1986) with Kryptofix® 2.2.2 and K2CO3 in a conical vial and 
azeotropically removing water with acetonitrile in a stream of nitrogen. Finally the dried 
[18F]KF was resolubilized in 500 µL of anhydrous acetonitrile and added to 3 (3.0 mg) 
in a conical glass vial. The vial was sealed and heated for 20 min at 90°C in an oil bath. 
After cooling the mixture was subjected to semi-preparative HPLC (Discovery C18, 4.6 
x 250 mm, 5µm, Supelco) using isocratic elution with acetonitrile/0.1%TFA (70/30) at a 
flow rate of 4 mL/min originated by a PU1580 pump (Jasco). The products were 
monitored by UV detector (UV2075, Jasco) at 254nm and by gamma-detection with a 
scintillation detector (Nuclear Interface). 
The radiolabeled product [18F]-1 eluting at 9-10 min was separated, diluted with 30mL 
of water and the whole solution was subjected to a C18 cartridge (200 mg. LiChrolut). 
The cartridge was washed with 5 mL of water, after that the radiolabeled product [18F]-
1 was eluted with 1mL of ethanol and reconstituted with 8mL of E153 electrolyte 
infusion solution (140mmol/l Na+, 5 mmol/l K+, 2.5mmol/l Ca++, 1.5mmol/l Mg++, 
50mmol/l acetate, 103mmol/l Cl-, Serumwerk Bernburg AG, Bernburg, Germany). This 
solution was used for biodistribution experiments and stability studies. 
Analytical HPLC analyses of the radiolabeled product [18F]-1 were performed by a 
Lichrograph® system (Merck-Hitachi) equipped with a L4500 UV detector, a L6200 
pump and a scintillation detector Gabi (Raytest) using a C18 column (Luna C18(2), 
4.6x250, 5µm) and the indicated isocratic eluent with a flow rate of 1.0 mL/min.  
The radiotracer [18F]-1 was synthesized in 70 min total synthesis time in 42% total 
decay corrected yield from [18F]fluoride in > 99% radiochemical purity (both isomers) 
and a specific activity 7-28 GBq/µmol at end of synthesis. 
 
2.3 Metabolite analysis 
Male Wistar-Unilever rats (n = 2; body weight 150 ± 12 g) were anesthetized with 
desflurane (9-10% v/v, 30% oxygen/air). The threshold value for breathing frequency 
was 65 breaths/min. Animals were put in supine position and placed on a heating pad to 
maintain body temperature. The spontaneously breathing rats were heparinized with 100 
units/kg heparin (Heparin-Natrium 25.000-ratiopharm®, ratiopharm GmbH, Germany) 
by subcutaneous injection to prevent blood clotting on intravascular catheters. After 
local anesthesia with lignocain (1%; Xylocitin® loc, mibe, Jena, Germany) into the right 
groin, a catheter (0.8 mm Umbilical Vessel Catheter, Tyco Healthcare, Tullamore, 
Ireland) was introduced into the right femoral artery for arterial blood sampling. A 
second needle catheter (35 G) was placed into a tail vein and was used for [18F]-1 
radiotracer injection (39 MBq in 0.5 mL of E153/10% ethanol, infusion 1 mL/min). 
Arterial blood samples were taken 1.5, 10, 30 and 60 min after injection. Arterial 
plasma was separated by centrifugation (11.000g x 3min) followed by precipitation of 
the proteins with methanol (2 volumes to 1 volume plasma) followed by 5 min storage 
at -60°C. The clear supernatant separated by centrifugation was used for analysis. The 
radio-HPLC system (Agilent 1100 series) applied for metabolite analysis was equipped 
with UV detection (254 nm) and an external radiochemical detector (RAMONA, 
Raytest GmbH, Straubenhardt, Germany). Analysis was performed on a Zorbax C18 
300SB (250 × 9.4 mm; 4 µm) column with an eluent system A (water + 0.1%TFA) and 
B (acetonitrile + 0.1% TFA) in the following gradient: 5 min 95% A, 10 min to 95% B, 
5 min at 95% B and 5 min to 95%A at a flow rate of 3 mL/min. 
 
2.4 Biodistribution studies in Wistar rats  
The animal research committee of the Regierungspräsidium Dresden approved the 
animal facilities and the experiments according to institutional guidelines and the 
German animal welfare regulations. The experimental procedure used conforms to the 
European Convention for the Protection of Vertebrate Animals used for Experimental 
and other Scientific Purposes (ETS No. 123), to the Deutsches Tierschutzgesetz, and to 
the Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health (DHEW Publication No. (NIH) 82-23, Revised 1996, Office of 
Science and Health Reports, DRR/NIH, Bethesda, MD 20205). The Wistar rats (Wistar 
Unilever, HsdCpb: Wu, Harlan Winkelmann GmbH, Borchen, Germany, 138±16 g 
body weight) were housed under standard conditions with free access to standard food 
and tap water. The biodistribution of [18F]-1 was studied in 7 male rats at 5 min and 8 
male rats at 60 min after tracer injection. The animals were anesthetised with Desflurane 
(Suprane, Baxter Healthcare Corporation Deerfield, IL, USA) (7.0-10.0% v/v in 30% 
oxygen) and 3-5 MBq radiotracer aliquots were administered in 500 µL electrolyte 
solution E153 (with 10% ethanol) and into a tail vein. After recovery from anaesthesia 
rats were again anaesthetized at 5 or 60 min after tracer injection, respectively. Blood 
was withdrawn by heart puncture, and the animals were euthanized. Organs and tissues 
were removed, dried, weighted, and the radioactivity was measured in a cross calibrated 
well counter (WIZARD, Automatic Gamma Counter, Perkin Elmer, Waltham, Ma, 
USA) or activimeter (Activimeter Isomed 2000; MCD Nuklear Medizintechnik, 
Dresden, Germany). The data were decay corrected and normalized to the amount of 
injected activity calculated from the activity of injection syringes before and after 
injection and expressed as percentage of injected activity (%ID) or injected activity per 
gram of tissue (%ID/g). Values are quoted as means ± standard deviation (mean ± SD) 
for a group of animals.  
 
3. Results and Discussion 
Recently, we have introduced new fluorinated styryl benzoxazole (compound 1) and 
styryl benzothiazole (compound 2) derivatives that were synthesized based on a 
multistep and convergent approach, using the Wittig reaction as a key step to introduce 
the styryl moiety (Scheme 1) (Ribeiro Morais, Miranda et al. 2011). Compounds 1 and 
2 were obtained as mixtures of geometric E and Z isomers, being the E isomer formed 
preferably in spite of the Z/E photoisomerization ability of these compounds. The 
assessment of the in vitro binding affinity of the E and Z isomers of 1 and 2 towards 
different types of amyloid fibrils (insulin, α-synuclein and β−amyloid peptide) has 
shown that compound 1 displays the highest Aβ binding affinity and selectivity. These 
studies have also proved that the Z/E geometric isomerism has almost no influence on 
the binding profile of 1 and 2 (Ribeiro Morais, Miranda et al. 2011). Altogether, these 
data led us to consider 1 the most promising compound to be further evaluated as an 
amyloid-avid probe for in vivo detection of Aβ deposits. Hence, we have studied the 
synthesis of the 18F-labelled counterpart ([18F]-1) of compound 1 and proceeded with its 
in vivo biological evaluation, as reported in here. 
 
Scheme 1. 
 
The radiosynthesis of the 18F-labelled styryl benzoxazole ([18F]-1) has been done using 
the tosylated precursor 3 as starting material, using a synthetic methodology similar to 
that previously reported to obtain the cold congener (1) (Ribeiro Morais, Miranda et al. 
2011). The optimization of the radiosynthesis involved the study of the influence of the 
temperature (80-100 ºC) and use of different solvents (dimethylformamide vs 
acetonitrile). Under optimized conditions, the synthesis of [18F]-1 was achieved by 
nucleophilic displacement of the tosylate group with dried K[18F] at 90 ºC for 20 min, 
using acetonitrile as solvent and K2.2.2/K2CO3 to catalyze the reaction (Scheme 2). 
This combination catalyst, commonly used in radiofluorination reaction, increases the 
solubility of the fluoride ion and enhances its nucleophilicity (Liu, Zhu et al. 2010). The 
radiotracer [18F]-1 has been purified by semipreparative HPLC using an isocratic 
elution with acetonitrile/0.1% TFA (70/30). After HPLC purification, [18F]-1 has been 
obtained as a mixture of the two E and Z isomers, as confirmed by HPLC (Fig. 2). No 
efforts have been made to separate the two E and Z isomers of [18F]-1 since they have 
the similar affinity towards Aβ(1-42) aggregates with binding constants of 4.48±0.38 
and 5.99±0.56 μM-1, respectively (Ribeiro Morais, Miranda et al. 2011). Prior to the 
biodistribution experiments and stability studies, [18F]-1 has been reformulated into an 
aqueous solution containing 10% of ethanol, using a solid phase extraction (SPE) C18 
cartridge to perform the reformulation. [18F]-1 was synthesized in an overall 42% 
decay-corrected radiochemical yield and high radiochemical purity (> 99%, both 
isomers) with a specific activity of 7-28 GBq/µmol at end of synthesis. The radiotracer 
[18F]-1 was synthesized in 70 min total synthesis time, which included the purification 
and reformulation. The radiochemical purity was determined based on radio-TLC and 
analytical HPLC experiments. The chemical identity of compound [18F]-1 was assessed 
by HPLC comparison with authentic samples of the E and Z isomers of the cold 
congener 1. 
 
Scheme 2. 
 
Biodistribution and metabolism studies of [18F]-1 were performed in male Wistar rats, 
in order to have a first insight into its potential relevance as a radiotracer for in vivo 
imaging of Aβ aggregates. In particular, these studies intended to elucidate if the 
compound could cross the BBB with a fast washout from the healthy brain, a crucial 
issue to reach intra cerebral amyloid deposits with minimal non-specific uptake.  
 
Figure 2. 
 
The biodistribution data of [18F]-1 in male Wistar rats are presented in Table 1. The data 
were obtained at 5 and 60 min post-injection (p.i), after intravenous bolus injection of 
the radiotracer. At early post-injection times, it was observed a moderately fast 
clearance of the 18F-radioactivity from the blood compartment with a value of 
0.49±0.20% ID/g at 5 min p.i. The percentages of injected dose (ID) that were found in 
the liver (4.83±2.16% at 5 min p.i. and 2.38±0.28% at 60 min p.i.) and intestine 
(5.30±2.63% at 5 min p.i. and 13.66±1.90% at 60 min p.i.) indicate a significant 
contribution of hepatobiliary excretion, as expected for a lipophilic compound. [18F]-1 
presents a calculated octanol/water partition coefficient (log Po/w) of 4.01, as we have 
reported previously (Ribeiro Morais, Miranda et al. 2011). [18F]-1 has shown a 
moderate initial brain uptake (0.61±0.26 %ID/g at 5 min p.i.), which is consistent with 
its lipophilicity. The activity retained in the brain was 0.45±0.04 %ID/g, 60 min after 
i.v. administration (Fig. 3). Therefore, [18F]-1 undergoes a relatively slow brain washout 
(5-to-60 min ratio = 1.36) in normal rat, which is a non favorable behavior for a specific 
radioprobe targeted at Aβ aggregates. In addition, [18F]-1 showed a significant femur 
uptake (0.50±0.21 %ID/g at 5 min p.i.; 0.75±0.13 %ID/g at 60 min p.i.) that increased 
with time (Fig. 3), indicating the ocurrence of in vivo defluorination. In vivo 
defluorination has been recently reported for related 18F-labeled styryltriazole 
derivatives carrying also the radioactive label at an aliphatic sp3 carbon atom (Lee, 
Choe et al. 2012). 
Table 1. 
Figure 3. 
Figure 4. 
The observed slow brain washout and increasing femur uptake indicated that [18F]-1 
was not stable in vivo, undergoing probably defluorination processes. To have a further 
insight into this point, we have performed radio-HPLC analysis of blood plasma from 
Wistar rats injected with [18F]-1. This study confirmed that [18F]-1 was rapidly 
metabolized into a polar metabolite (see Supporting Information), being depicted in Fig. 
4 the variation of the metabolite fraction over time. After 30 min p.i., the plasma 
activity was due almost exclusively to the metabolite, which indicates that [18F]-1 has a 
poor in vivo stability. 
 
4. Conclusions 
A novel radiofluorinated styryl-benzoxazole derivative ([18F]-1) targeted at Aβ 
aggregates has been synthesized in good yield and with high radiochemical purity and 
specific activity. Biodistribution and metabolism studies in rat have shown that this 
newly synthesized radiotracer can cross the BBB but displays a rather slow brain 
washout. Moreover, [18F]-1 suffers extensive metabolization/defluorination in vivo and, 
therefore, is not a suitable radioprobe for in vivo imaging of Aβ deposits in AD-affected 
brain. To overcome these drawbacks, we envisage to explore the use of different 
aliphatic linkers between the -CH218F group and the phenyl ring, as it has been 
reported that such linkers can strongly influence the in vivo stability of this type of 
compounds (Lee, Choe et al. 2012). 
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